Poseida Therapeutics, Inc.

NasdaqGS:PSTX 株式レポート

時価総額:US$267.6m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Poseida Therapeutics 将来の成長

Future 基準チェック /16

Poseida Therapeuticsの収益は年間6.4%で減少すると予測されていますが、年間収益は年間19.2%で増加すると予想されています。EPS は年間10.3%で増加すると予想されています。

主要情報

-6.4%

収益成長率

10.3%

EPS成長率

Biotechs 収益成長24.6%
収益成長率19.2%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日22 May 2024

今後の成長に関する最新情報

Recent updates

Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

May 21
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%

Apr 09
Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%

Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement

Mar 17

Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

Jan 24
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too

Dec 18
Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too

New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Aug 13
New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding

Apr 17
Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding

Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering Tech

Sep 04

Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M

Aug 11

Poseida jumps 56% as Roche eyes CAR-T drugs in deal worth up to $6B

Aug 03

Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25

May 15
Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25

Poseida Therapeutics: Genome Engineering For Safer Cell Therapies

Oct 30

What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?

Mar 19
What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?

Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?

Jan 25
Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?

Poseida Therapeutics (PSTX) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow

Dec 09

FDA lifts clinical hold on Poseida's prostate cancer cell therapy study

Nov 02

業績と収益の成長予測

NasdaqGS:PSTX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/202618-218-168-1613
12/31/202529-226-125-1504
12/31/202474-152-87-873
3/31/202483-109-72-69N/A
12/31/202365-123-95-92N/A
9/30/202350-131-64-61N/A
6/30/2023157-29-11-7N/A
3/31/2023139-45-17-13N/A
12/31/2022130-64-31-27N/A
9/30/2022152-29-25-21N/A
6/30/202235-142-126-123N/A
3/31/202233-145-118-115N/A
12/31/202131-125-105-103N/A
9/30/2021N/A-163-146-141N/A
6/30/2021N/A-155-137-130N/A
3/31/2021N/A-139-143-129N/A
12/31/2020N/A-130-130-113N/A
9/30/2020N/A-117-116-100N/A
6/30/2020N/A-104-105-89N/A
3/31/2020N/A-102-81-73N/A
12/31/2019N/A-87-70-65N/A
9/30/2019N/A-76-65-60N/A
12/31/2018N/A-44-39-38N/A
9/30/2018N/A-36-31-31N/A
12/31/20173-20N/A-23N/A
12/31/201610-5N/A-10N/A

アナリストによる今後の成長予測

収入対貯蓄率: PSTX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PSTX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: PSTX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PSTXの収益 ( 19.2% ) US市場 ( 8.5% ) よりも速いペースで成長すると予測されています。

高い収益成長: PSTXの収益 ( 19.2% ) 20%よりも低い成長が予測されています。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: PSTXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です


成長企業の発掘